Clinical Trial DRUG CA180406
- Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
- Principal Investigator
- Jessica Altman
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CA180406
- The purpose of this study is to evaluate dasatinib treatment discontinuation among patients who have achieved a sustained stable complete molecular response (CMR) for 12 months or longer.
- Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It is a form of leukemia. Approximately 85% of patients with CML are in the chronic phase at the time of diagnosis. During this phase, patients are usually asymptomatic or have only mild symptoms of fatigue, left side pain, joint and/or hip pain, or abdominal fullness. The duration of chronic phase is variable and depends on how early the disease was diagnosed as well as the therapies used. Dasatinib (SPRYCEL® ) has been studied in a number of CML subjects and has been approved in approximately 69 countries (including by the United States Food and Drug Administration (FDA) and the European Commission) for the treatment of adults with CML with resistance or intolerance to prior therapy including imatinib. For the treatment of adult patients with newly diagnosed chronic phase CML, SPRYCEL is approved in the US and Europe. Marketing authorization approval for the indication of adult patients with newly diagnosed CP-CML is currently under review in several other countries. Patients with chronic phase CML who have achieved a CMR after dasatinib or other tyrosine kinase inhibitor (TKI) therapy often ask whether it is still necessary for their treatment to continue, and that question has been the focus of some recent research.
Some of the eligibility criteria include:
- Participants must be diagnosed with chronic phase CML, on treatment with dasatinib for at least 2 years and in dasatinib-induced complete molecular remission for at least 1 year prior to study entry.
- Participants must be 18 or older.
- Description of Treatment
- Participants enrolled in this study will have their dasatinib treatment discontinued. They will be followed for 5 years to monitor the maintenance of Major Molecular Response (MMR). If MMR is lost, dasatinib treatment will be resumed at the dose level the participant was receiving before enrollment and remain on treatment for the remainder of the study. The doctor may adjust treatment as needed. All study procedures will continue.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jessica Altman
- A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
- A Phase IIa, Multicenter, Open-Label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
- A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse
- A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
- A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
- Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age = 60 Years)
- A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
- A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
last updated: 30-Jan-15 02:02 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.